Company profile for Orsenix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. Our investigational ATO, ORH-2014, is a patented, oral capsule that achieved the required target exposure at a dose of 15 mg once daily in a recently completed Phase 1 Study. ORH-2014 has been granted Orphan Drug Designation by both FDA and EMEA, and Orsenix gained a...
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. Our investigational ATO, ORH-2014, is a patented, oral capsule that achieved the required target exposure at a dose of 15 mg once daily in a recently completed Phase 1 Study. ORH-2014 has been granted Orphan Drug Designation by both FDA and EMEA, and Orsenix gained alignment with the FDA to proceed with a single registrational study for accelerated approval of ORH-2014 for the treatment of newly diagnosed patients with APL, assuming favorable regulatory review.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1105 N. Market Street, Suite 1800, Wilmington, Delaware 19807
Telephone
Telephone
302-510-8961
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Arab Health

Arab Health

Not Confirmed

envelop Contact Supplier

Arab Health

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty